Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia.

Glück AA, Orlando E, Leiser D, Poliaková M, Nisa L, Quintin A, Gavini J, Stroka DM, Berezowska S, Bubendorf L, Blaukat A, Aebersold DM, Medová M, Zimmer Y.

Oncogene. 2018 May 2. doi: 10.1038/s41388-018-0256-6. [Epub ahead of print]

PMID:
29717265
2.

Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer.

Piguet AC, Medová M, Keogh A, Glück AA, Aebersold DM, Dufour JF, Zimmer Y.

Genes Cancer. 2015 Jul;6(7-8):317-327.

3.

Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.

Mikami K, Medová M, Nisa L, Francica P, Glück AA, Tschan MP, Blaukat A, Bladt F, Aebersold DM, Zimmer Y.

Mol Cancer Res. 2015 Dec;13(12):1544-53. doi: 10.1158/1541-7786.MCR-15-0022. Epub 2015 Sep 10.

4.

Interplay between receptor tyrosine kinases and hypoxia signaling in cancer.

Glück AA, Aebersold DM, Zimmer Y, Medová M.

Int J Biochem Cell Biol. 2015 May;62:101-14. doi: 10.1016/j.biocel.2015.02.018. Epub 2015 Mar 6. Review.

PMID:
25747905
5.

Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation.

Leiser D, Pochon B, Blank-Liss W, Francica P, Glück AA, Aebersold DM, Zimmer Y, Medová M.

FEBS Lett. 2014 Mar 3;588(5):653-8. doi: 10.1016/j.febslet.2013.12.025. Epub 2014 Jan 17.

Supplemental Content

Loading ...
Support Center